Cristina Grávalos Castro, F. Pérez-Alcántara, José Antonio Gasquet Espuña, Ignasi Campos Tapias
{"title":"panitumumab与西妥昔单抗联合一线和二线化疗在西班牙KRAS转移性结直肠癌中的成本最小化研究","authors":"Cristina Grávalos Castro, F. Pérez-Alcántara, José Antonio Gasquet Espuña, Ignasi Campos Tapias","doi":"10.1007/S40277-013-0024-5","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":101511,"journal":{"name":"PharmacoEconomics Spanish Research Articles","volume":"18 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Estudio de minimización de costes de panitumumab frente a cetuximab en combinación con quimioterapia en primera línea y segunda línea en el cáncer colorrectal metastásico KRAS nativo en España\",\"authors\":\"Cristina Grávalos Castro, F. Pérez-Alcántara, José Antonio Gasquet Espuña, Ignasi Campos Tapias\",\"doi\":\"10.1007/S40277-013-0024-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":101511,\"journal\":{\"name\":\"PharmacoEconomics Spanish Research Articles\",\"volume\":\"18 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PharmacoEconomics Spanish Research Articles\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/S40277-013-0024-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics Spanish Research Articles","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/S40277-013-0024-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Estudio de minimización de costes de panitumumab frente a cetuximab en combinación con quimioterapia en primera línea y segunda línea en el cáncer colorrectal metastásico KRAS nativo en España